Literature DB >> 30144404

Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.

Kelly J Peyton1, Xiao-Ming Liu1, Yajie Yu1, Benjamin Yates1, Ghazaleh Behnammanesh1, William Durante2.   

Abstract

Glutaminase-1 (GLS1) is a mitochondrial enzyme found in endothelial cells (ECs) that metabolizes glutamine to glutamate and ammonia. Although glutaminolysis modulates the function of human umbilical vein ECs, it is not known whether these findings extend to human ECs beyond the fetal circulation. Furthermore, the molecular mechanism by which GLS1 regulates EC function is not defined. In this study, we show that the absence of glutamine in the culture media or the inhibition of GLS1 activity or expression blocked the proliferation and migration of ECs derived from the human umbilical vein, the human aorta, and the human microvasculature. GLS1 inhibition arrested ECs in the G0/G1 phase of the cell cycle and this was associated with a significant decline in cyclin A expression. Restoration of cyclin A expression via adenoviral-mediated gene transfer improved the proliferative, but not the migratory, response of GLS1-inhibited ECs. Glutamine deprivation or GLS1 inhibition also stimulated the production of reactive oxygen species and this was associated with a marked decline in heme oxygenase-1 (HO-1) expression. GLS1 inhibition also sensitized ECs to the cytotoxic effect of hydrogen peroxide and this was prevented by the overexpression of HO-1. In conclusion, the metabolism of glutamine by GLS1 promotes human EC proliferation, migration, and survival irrespective of the vascular source. While cyclin A contributes to the proliferative action of GLS1, HO-1 mediates its pro-survival effect. These results identify GLS1 as a promising therapeutic target in treating diseases associated with aberrant EC proliferation, migration, and viability.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-Diazo-5-oxo-L-norleucine (DON, PubChem CID: 5359375); CB-839 (PubChem CID: 71577426); Endothelial cells; Glutaminase; Migration; Proliferation; bis-2-(5-Phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES, PubChem CID: 3372016)

Mesh:

Substances:

Year:  2018        PMID: 30144404      PMCID: PMC6248344          DOI: 10.1016/j.bcp.2018.08.032

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  66 in total

1.  Compound C stimulates heme oxygenase-1 gene expression via the Nrf2-ARE pathway to preserve human endothelial cell survival.

Authors:  Xiao-Ming Liu; Kelly J Peyton; Ahmad R Shebib; Hong Wang; William Durante
Journal:  Biochem Pharmacol       Date:  2011-05-24       Impact factor: 5.858

2.  Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.

Authors:  Laura M Shelton; Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

3.  The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.

Authors:  R C Willis; J E Seegmiller
Journal:  J Cell Physiol       Date:  1977-12       Impact factor: 6.384

Review 4.  Is glutamine a conditionally essential amino acid?

Authors:  J M Lacey; D W Wilmore
Journal:  Nutr Rev       Date:  1990-08       Impact factor: 7.110

5.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

6.  Hypochlorous acid-induced heme oxygenase-1 gene expression promotes human endothelial cell survival.

Authors:  Yong Wei; Xiao-ming Liu; Kelly J Peyton; Hong Wang; Fruzsina K Johnson; Robert A Johnson; William Durante
Journal:  Am J Physiol Cell Physiol       Date:  2009-07-22       Impact factor: 4.249

7.  Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C.

Authors:  W Durante; M H Kroll; P M Vanhoutte; A I Schafer
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

8.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

Authors:  Mary M Robinson; Steven J McBryant; Takashi Tsukamoto; Camilo Rojas; Dana V Ferraris; Sean K Hamilton; Jeffrey C Hansen; Norman P Curthoys
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

Review 9.  The glutamine commute: take the N line and transfer to the A.

Authors:  Farrukh A Chaudhry; Richard J Reimer; Robert H Edwards
Journal:  J Cell Biol       Date:  2002-04-29       Impact factor: 10.539

10.  Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

Authors:  Daniel Herranz; Alberto Ambesi-Impiombato; Jessica Sudderth; Marta Sánchez-Martín; Laura Belver; Valeria Tosello; Luyao Xu; Agnieszka A Wendorff; Mireia Castillo; J Erika Haydu; Javier Márquez; José M Matés; Andrew L Kung; Stephen Rayport; Carlos Cordon-Cardo; Ralph J DeBerardinis; Adolfo A Ferrando
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

View more
  11 in total

1.  Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.

Authors:  Larissa Menezes Dos Reis; Douglas Adamoski; Rodolpho Ornitz Oliveira Souza; Carolline Fernanda Rodrigues Ascenção; Krishina Ratna Sousa de Oliveira; Felipe Corrêa-da-Silva; Fábio Malta de Sá Patroni; Marília Meira Dias; Sílvio Roberto Consonni; Pedro Manoel Mendes de Moraes-Vieira; Ariel Mariano Silber; Sandra Martha Gomes Dias
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

2.  High-Throughput Screening Reveals New Glutaminase Inhibitor Molecules.

Authors:  Renna K E Costa; Camila T Rodrigues; Jean C H Campos; Luciana S Paradela; Marilia M Dias; Bianca Novaes da Silva; Cyro von Zuben de Valega Negrao; Kaliandra de Almeida Gonçalves; Carolline F R Ascenção; Douglas Adamoski; Gustavo Fernando Mercaldi; Alliny C S Bastos; Fernanda A H Batista; Ana Carolina Figueira; Artur T Cordeiro; Andre L B Ambrosio; Rafael V C Guido; Sandra M G Dias
Journal:  ACS Pharmacol Transl Sci       Date:  2021-12-01

Review 3.  Cardio-Oncology: Understanding the Intersections Between Cardiac Metabolism and Cancer Biology.

Authors:  Anja Karlstaedt; Matthew Barrett; Ray Hu; Seth Thomas Gammons; Bonnie Ky
Journal:  JACC Basic Transl Sci       Date:  2021-07-28

Review 4.  Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.

Authors:  Vinod S Bisht; Kuldeep Giri; Deepak Kumar; Kiran Ambatipudi
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

Review 5.  Interplay Between Reactive Oxygen/Reactive Nitrogen Species and Metabolism in Vascular Biology and Disease.

Authors:  Masuko Ushio-Fukai; Dipankar Ash; Sheela Nagarkoti; Eric J Belin de Chantemèle; David J R Fulton; Tohru Fukai
Journal:  Antioxid Redox Signal       Date:  2021-06-01       Impact factor: 7.468

6.  Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1.

Authors:  Ghazaleh Behnammanesh; Giovanna L Durante; Yash P Khanna; Kelly J Peyton; William Durante
Journal:  Redox Biol       Date:  2020-04-02       Impact factor: 11.799

Review 7.  The Emerging Role of l-Glutamine in Cardiovascular Health and Disease.

Authors:  William Durante
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

Review 8.  Where Metabolism Meets Senescence: Focus on Endothelial Cells.

Authors:  Jacopo Sabbatinelli; Francesco Prattichizzo; Fabiola Olivieri; Antonio Domenico Procopio; Maria Rita Rippo; Angelica Giuliani
Journal:  Front Physiol       Date:  2019-12-18       Impact factor: 4.566

9.  Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.

Authors:  Ghazaleh Behnammanesh; Zane E Durante; Kelly J Peyton; Luis A Martinez-Lemus; Scott M Brown; Shawn B Bender; William Durante
Journal:  Front Pharmacol       Date:  2019-04-16       Impact factor: 5.810

Review 10.  Therapeutic Potential of Selenium in Glioblastoma.

Authors:  Eduard Yakubov; Thomas Eibl; Alexander Hammer; Markus Holtmannspötter; Nicolai Savaskan; Hans-Herbert Steiner
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 5.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.